October 29th 2024
Asciminib has gained accelerated approval from the FDA for the treatment of patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
September 18th 2024
Ibrutinib Combination Significantly Reduces Progression in CLL
June 4th 2015The combination of ibrutinib with bendamustin plus rituximab (BR) demonstrated a significant improvement in progression-free survival compared with BR alone in patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
Winter Hematology Meeting Highlighted by Talks on Immunotherapy, Personalized Medicine
February 21st 2015Experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.
Read More
Upfront Fulvestrant Improves OS Compared With Anastrozole in HR-Positive MBC
December 13th 2014Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer. These findings from the phase II FIRST trial were presented at the 2014 San Antonio Breast Cancer Symposium.
Read More
New Treatments for AML Remain Elusive, But Researchers Are Undeterred
November 6th 2014When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what’s ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases.
Read More
CAR Therapy CTL019 Elicits Complete Remissions in ALL
October 20th 2014The investigational chimeric antigen receptor (CAR) therapy CTL019 elicited complete remissions in 27 of 30 pediatric and adult patients (90%) with relapsed/refractory acute lymphoblastic leukemia (ALL) in 2 pilot trials.
Read More
Results of the Phase II GAGE Trial in CLL
June 11th 2014Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).
Watch
Efficacy Findings from the RESONATE Trial
June 5th 2014Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the RESONATE trial, a phase III trial that compared ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma.
Watch
Ibrutinib Dramatically Increases PFS, OS in Phase III CLL Study
June 1st 2014Treatment with single-agent ibrutinib (Imbruvica) dramatically increased progression-free survival (PFS) by nearly 80% and significantly extended overall survival (OS) by 57% compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Read More
Initial Results from the CALGB 10801 Study
May 14th 2014Timothy S. Pardee, MD, Assistant Professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, describes initial results of the CALGB 10801 (Alliance) study, which added dasatinib to standard induction and consolidation therapy for newly diagnosed patients with core binding factor (CBF) acute myeloid leukemia (AML).
Watch